VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2014

Oct 1, 2014

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2014-09-30

Reporting Person: Horton Kenneth L (EVP & Chief Legal Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2014-09-30	Common Stock	M	36000	$55.83	Acquired	68463	Direct
2014-09-30	Common Stock	S	4713	$111.33	Disposed	63750	Direct
2014-09-30	Common Stock	S	14286	$112.22	Disposed	49464	Direct
2014-09-30	Common Stock	S	9601	$113.10	Disposed	39863	Direct
2014-09-30	Common Stock	S	7400	$113.91	Disposed	32463	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2014-09-30	Stock Option (right to buy)	$55.83	M	36000	Disposed	2022-06-10	Common Stock (36000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	366	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Horton's company approved trading plan under Rule 10b5-1.

F2: Open market sales reported on this line occurred at a weighted average price of $111.33 (range $110.61 to $111.60).

F3: Mr. Horton undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

F4: Open market sales reported on this line occurred at a weighted average price of $112.22 (range $111.61 to $112.60).

F5: Open market sales reported on this line occurred at a weighted average price of $113.10 (range $112.61 to $113.60).

F6: Open market sales reported on this line occurred at a weighted average price of $113.91 (range $113.62 to $114.41).

F7: The option vests in 16 quarterly installments from 06/11/2012.